Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 861 to 870 of 1334 total matches.

Carboplatin

   
The Medical Letter on Drugs and Therapeutics • Sep 08, 1989  (Issue 800)
COPYRIGHT LAWS Other studies have found carboplatin active in small-cell and non-small-cell lung cancer ...
Carboplatin (Paraplatin - Bristol-Myers), a cytotoxic platinum-containing drug chemically related to cisplatin (Platinol), was recently approved by the US Food and Drug Administration (FDA) for palliative treatment of patients with recurrent ovarian cancer, including those previously treated with cisplatin.
Med Lett Drugs Ther. 1989 Sep 8;31(800):83-4 |  Show IntroductionHide Introduction

Three New ACE Inhibitors For Hypertension

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991  (Issue 852)
— Benazepril, fosinopril, and ramipril, like enalapril, are prodrugs that are converted to active forms ...
Benazepril (Lotensin - Ciba-Geigy), fosinopril (Monopril - Mead Johnson), and - Hoechst, Upjohn) are new angiotensin-converting enzyme (ACE) inhibitors recently approved by the US Food and Drug Administration (FDA) for once-a-day treatment of hypertension. Three other ACE inhibitors, captopril (Capoten), enalapril (Vasotec), and lisinopril (Prinivil, Zestril) were previously available in the USA for this indication. Captopril and enalapril have also been approved by the FDA for treatment of congestive heart failure.
Med Lett Drugs Ther. 1991 Sep 6;33(852):83-4 |  Show IntroductionHide Introduction

Ziac for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 1994  (Issue 918)
beta-blocker with no intrinsic sympathomimetic activity, has also been marketed as a single drug ...
Ziac (Lederle), a combination of the beta-blocker bisoprolol fumarate and a very low dose (6.25 mg) of the diuretic hydrochlorothiazide, has been approved for treatment of hypertension by the US Food and Drug Administration (FDA). Bisoprolol, a new cardioselective beta-blocker with no intrinsic sympathomimetic activity, has also been marketed as a single drug (Zebeta - Lederle). The manufacturer is promoting the combination for initial treatment of hypertension with the claim that the low doses of the two drugs used together are effective in lowering blood pressure, but are each too low ...
Med Lett Drugs Ther. 1994 Mar 18;36(918):23-4 |  Show IntroductionHide Introduction

Intranasa Budesonide for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 1994  (Issue 926)
for inhalation treatment of both allergic rhinitis and asthma. ACTIVITY AND PHARMACOKINETICS — Like ...
An intranasal formulation of the corticosteroid budesonide (Rhinocort Nasal Inhaler - Astra) was recently approved by the US Food and Drug Administration for treatment of seasonal or perennial allergic rhinitis in adults and children and nonallergic perennial rhinitis in adults. Budesonide has been available in Canada and Europe for several years for inhalation treatment of both allergic rhinitis and asthma.
Med Lett Drugs Ther. 1994 Jul 8;36(926):63-4 |  Show IntroductionHide Introduction

Calcipotriene for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994  (Issue 928)
calcitriol, the metabolically active form of vitamin D 3 , it inhibits proliferation and enhances ...
Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration (FDA) for treatment of moderate plaque psoriasis, the most common form of the disease.
Med Lett Drugs Ther. 1994 Aug 5;36(928):70-1 |  Show IntroductionHide Introduction

Valproate for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 1994  (Issue 929)
aminotransferase activity are common in patients taking valproate, but usually are not associated with other signs ...
Although lithium (Eskalith, and others) is the standard treatment for bipolar (manic-depressive) disorder, 20% to 40% of patients do not respond adequately or cannot tolerate its adverse effects (Medical Letter, 33:43, 1991). Results of recent studies suggest that valproate (Depakene - valproic acid; Depakote - divalproex sodium), a widely used anticonvulsant (Medical Letter, 31:1, 1989), might be an effective alternative. Other anticonvulsants, particularly carbamazepine (Tegretol, and others), have also been used as second-line drugs for treatment of mania and other psychiatric ...
Med Lett Drugs Ther. 1994 Aug 19;36(929):74-5 |  Show IntroductionHide Introduction

Acarbose for Diabetes Mellitus

   
The Medical Letter on Drugs and Therapeutics • Feb 02, 1996  (Issue 967)
in aminotransferase activity have also been reported. INTERACTIONS — When given with insulin or sulfonylureas ...
Acarbose (Precose -Bayer), an oral alpha-glucosidase inhibitor that has been available in Europe for several years, was recently approved by the US Food and Drug Administration (FDA) for treatment of non-insulin-dependent diabetes mellitus (NIDDM).
Med Lett Drugs Ther. 1996 Feb 2;38(967):9-10 |  Show IntroductionHide Introduction

Tiludronate for Paget's Disease of Bone

   
The Medical Letter on Drugs and Therapeutics • Jul 18, 1997  (Issue 1005)
(tye loo’ droe nate) inhibits the activity of osteoclasts and decreases bone turnover. Unlike ...
Tiludronate (Skelid - Sanofi), a chloro-4-phenylthiomethylene bisphosphonate, has been approved by the US Food and Drug Administration (FDA) for treatment of Paget's disease of bone. Characterized by excessive bone resorption and disorganized bone remodeling, Paget's disease occurs in up to 3% of people more than 55 years old in Europe and North America (PD Delmas and PJ Meunier, N Engl J Med, 336:558, Feb 20, 1997).
Med Lett Drugs Ther. 1997 Jul 18;39(1005):65-6 |  Show IntroductionHide Introduction

Bupropion (Zyban) for Smoking Cessation

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 1997  (Issue 1007)
. All three active treatments led to a statistically significant difference from placebo in cessation rates ...
Bupropion hydrochloride, currently available as an antidepressant (Wellbutrin - Medical Letter, 31:97, 1989; Wellbutrin SR), is now being marketed in a sustainedrelease formulation as Zyban (Glaxo Wellcome) for use as an aid in smoking cessation.
Med Lett Drugs Ther. 1997 Aug 15;39(1007):77-8 |  Show IntroductionHide Introduction

Quetiapine for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Dec 19, 1997  (Issue 1016)
, constipation, postural hypotension, dry mouth and increases in serum aminotransferase activity have occurred ...
Quetiapine (Seroquel - Zeneca), a dibenzothiazepine derivative, has been approved by the FDA for treatment of schizophrenia and other psychotic disorders. It is a new addition to the 'atypical' antipsychotics, which include olanzapine (Zyprexa - Medical Letter, 39:5, 1997), risperidone (Risperdal) and clozapine (Clozaril). Atypical antipsychotic drugs generally are less likely to cause extrapyramidal symptoms than older drugs such as haloperidol (Haldol, and others) or the phenothiazines.
Med Lett Drugs Ther. 1997 Dec 19;39(1016):117-8 |  Show IntroductionHide Introduction